Prothena Corporation plc Logo

Email this page: News Release

Results for Prothena's Phase 1b Multiple Ascending Dose Study of PRX002/RG7935 in Patients with Parkinson's Disease to be Presented at the 13th​ International Conference on Alzheimer's and Parkinson's Diseases

For security reasons, registration is required before you can use this feature.
* Indicates required field